MENU
Aim higher

Triple-T2

Rationalized Tailored Targeted Therapy for Cancer: The Triple-T Service

Triple-T combines the expertise of 2 companies specialized in kinase activity and genomic profiling with academically developed technologies to provide doctors and patients with information on druggable and drug-resistance pathways of individual lung tumors. This first commercial service of its kind will enable clinicians to rationally choose kinase inhibitor(s) to treat (therapy resistant) patients better. Services will be later extended to other cancers.
Project ID: 
9 470
Ranking: 
44
Cut-off: 
2
Start date: 
01-04-2015
Project Duration: 
36months
Project costs: 
1 555 450.00€
Technological Area: 
Cellular and Molecular Biology
Market Area: 
Diagnostic services